Drug Profile
Research programme: antibody therapeutics - Kodiak Sciences
Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Kodiak Sciences
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for research development in Eye-disorders in Canada
- 29 Oct 2020 Antibody therapeutics is still in early research for Eye disorders in Canada
- 29 Oct 2020 AbCellera and Kodiak Sciences enter into antibody discovery Collaboration for Ophthalmology